
Opinion|Videos|August 16, 2024
Expert Perspective on the Expanding Treatment Landscape in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the expanding treament landscape for mCRPC.
Advertisement
Episodes in this series

Now Playing
- Given the evolution/expansion of the prostate cancer treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), can you discuss key factors that shape your treatment approach?
- How do patient characteristics such as age, performance status, and comorbidities influence that decision?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5

















